Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases

52Citations
Citations of this article
105Readers
Mendeley users who have this article in their library.

Abstract

Despite recent leaps in modern medicine, progress in the treatment of neurological diseases remains slow. The near impermeable blood-brain barrier (BBB) that prevents the entry of therapeutics into the brain, and the complexity of neurological processes, limits the specificity of potential therapeutics. Moreover, a lack of etiological understanding and the irreversible nature of neurological conditions have resulted in low tolerability and high failure rates towards existing small molecule-based treatments. Neuropeptides, which are small proteinaceous molecules produced by the body, either in the nervous system or the peripheral organs, modulate neurological function. Although peptide-based therapeutics originated from the treatment of metabolic diseases in the 1920s, the adoption and development of peptide drugs for neurological conditions are relatively recent. In this review, we examine the natural roles of neuropeptides in the modulation of neurological function and the development of neurological disorders. Furthermore, we highlight the potential of these proteinaceous molecules in filling gaps in current therapeutics.

Cite

CITATION STYLE

APA

Yeo, X. Y., Cunliffe, G., Ho, R. C., Lee, S. S., & Jung, S. (2022, February 1). Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases. Biomedicines. MDPI. https://doi.org/10.3390/biomedicines10020343

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free